Thallion Pharmaceuticals Inc. To Trade On TSX Venture Exchange
THALLION PHARMACEUTICALS INC. ("TLN")
BULLETIN TYPE: New Listing-Shares
BULLETIN DATE: December 11, 2012
TSX Venture Tier 2 Company
The common shares of Thallion Pharmaceuticals Inc. (the "Company") will be listed and admitted to trading on TSX Venture Exchange, on the effective dates stated below.
Listing Date:At the close of business (5:01 p.m. EST) on Tuesday, December 11,
Commence Date:The common shares will commence trading on TSX Venture Exchange at the opening Wednesday, December 12, 2012.
Please note that the common shares of the Company (Symbol: TLN) will be delisted from Toronto Stock Exchange at the close of business on Tuesday, December 11, 2012, and will be listed on TSX Venture Exchange at the same time.
Capitalization:Unlimited common shares without nominal value of which 32,194,566 common shares are issued and outstanding
Transfer Agent:Computershare Trust Company of Canada (Montreal and Toronto)
Trading Symbol: TLN
CUSIP Number: 88327P105
The Company is classified as a "Research and Development in the Physical, Engineering and Life Sciences" issuer (NAICS Number: 541710). For further information, please refer to the Company's continuous disclosure information available on SEDAR.
Company Contact:Mr. Michael Singer
Chief Financial Officer
Company Address:1375 TransCanada Highway, Suite 200, Dorval, Quebec H9P 2W8